Halo Labs, a life science instrumentation company raised $6 million in series C financing. The round was led by Agilent Technologies Inc. and includes participation from existing investors Research Corporation Technologies, Broad Oak Capital Partners, BioAdvance, and members of the Board of Directors and senior management.
 
This new funding will be used for continued commercialization of Halo Labs’ Aura platform, increasing manufacturing capacity and developing new products to meet the current and new needs of pharmaceutical researchers.
 
“We are excited to have Agilent as a partner in this journey as we scale our business in some exciting new directions.”
 
“For the past two years, Halo Labs has deployed an aggressive growth strategy and has raised the bar for innovation in our market,” said Rick Gordon, CEO of Halo Labs. “The fact that we were able to close on a funding round in the current economic environment demonstrates the success of that strategy. Our instruments have been adopted by virtually every major biopharmaceutical company and are now one of the leading tools in cell and gene therapy. With this capital, we will continue our current trajectory and scale our business in some exciting new directions. We are excited to have Agilent as a partner in that journey.”
 
First launched in 2017, Aura from Halo Labs combined multiple stability, quality, and safety assays into one instrument for pharmaceutical product development. It’s available in six different models, representing tools specific for different therapeutic modalities and development stages. Aura instruments give pharmaceutical scientists access to a large amount of data in minutes with the goal of allowing for new therapies to move from the lab to the clinic faster and more safely.